MECP2 and epilepsy: Our analysis demonstrated that patients having pathogenic mutations in MECP2, CDKL5, PRODH, KCNQ2 are not controlled well with existing AEDs, which lead to the recurrence of epilepsy after therapy with current AEDs (Table 2).